The foundation-funded initiative from Jackson Laboratories has advanced a model for educating oncologists and providing access to tumor genomic profiling in the community setting.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
